ARQ-252 is a topical janus kinase 1 (JAK1) inhibitor that has promise as a novel treatment for inflammatory dermatologic diseases, including chronic hand eczema and vitiligo. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and atopic dermatitis.
ARQ-252 is differentiated from other topical JAK inhibitors by its high potency and unique high selectivity against JAK1 compared to JAK2. ARQ-252’s selectivity for JAK1 may confer important safety advantages compared to other topical JAK inhibitors.
Download our corporate fact sheet.
Download